JeffTai
2023-03-29

ok
@StickyRice：
Eli Lilly, Novo could make more money on insulin despite price reductions Eli Lilly $Eli Lilly(LLY)$ and Novo Nordisk $Novo-Nordisk A/S(NVO)$ are set to make even more money off their insulin products despite price curbs by avoiding paying rebates to Medicaid. Lilly can avoid $430M annually in new Medicaid rebates and make more than $85M in additional profit per year, Bloomberg related, based on an analysis by consulting firm Veda Partners. Spencer Perlman, director of health-care research at Veda, told the news service that Novo (NVO) could avoid about $350M in new 2024 rebates on NovoLog and Levemir while adding earnings of ~$210M. Perlman noted that currently, the two companies don't make any money on Medicare sales. Both Lilly (LLY) and Novo (NVO) have recently announced that they are cutting their insulin prices in the face of pressure from lawmakers.
Eli Lilly, Novo could make more money on insulin despite price reductions Eli Lilly $Eli Lilly(LLY)$ and Novo Nordisk $Novo-Nordisk A/S(NVO)$ are set to make even more money off their insulin products despite price curbs by avoiding paying rebates to Medicaid. Lilly can avoid $430M annually in new Medicaid rebates and make more than $85M in additional profit per year, Bloomberg related, based on an analysis by consulting firm Veda Partners. Spencer Perlman, director of health-care research at Veda, told the news service that Novo (NVO) could avoid about $350M in new 2024 rebates on NovoLog and Levemir while adding earnings of ~$210M. Perlman noted that currently, the two companies don't make any money on Medicare sales. Both Lilly (LLY) and Novo (NVO) have recently announced that they are cutting their insulin prices in the face of pressure from lawmakers.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

  • Top
  • Latest
empty
No comments yet